Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare- dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformatio ...